Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 August 2021 | Story Leonie Bolleurs | Photo Supplied
Tinus Viljoen (second from the left) is responsible for waste management at the university. Here he is pictured at the new chemical waste facility on the western side of the Bloemfontein Campus. With him, on his left, is Nico Janse van Rensburg, Senior Director, University Estates; Prof Danie Vermeulen, Dean of the Faculty of Natural and Agricultural Sciences; and on the far right is Benedict Mochesela, officer at University Estates.

A new chemical waste facility on the western side of the Bloemfontein Campus started functioning in July 2021 and will enhance the safe storage of hazardous materials on campus.

Since the safety of its staff and students are a key priority for the university, as stipulated in its strategic plan, a facility such as this plays an essential role in reducing any health risks and even the possibility of an explosion.

Tinus Viljoen, a Lecturer in the Department of Genetics, concurs that this facility makes the university a safer place because there are less toxic and flammable waste lying around in the labs. 

Besides his role as lecturer, he is responsible for waste management, including the collection of hazardous waste internally, classifying it, and arranging for it to be collected by accredited waste companies. 

A safer space

Waste previously stored in the Genetics Building is now kept at the new facility. Viljoen is of the opinion that this new space is safer because fewer students and staff have access to the western campus. “The chemical waste tends to smell, and on this part of the campus it is out of the way,” he says.

He also says that it helps to have a central place to store the waste, because of logistical reasons. “It makes the overall waste management easier.”

It is mainly inorganic and organic liquid/solid waste, contaminated glass, contaminated solids (e.g., filter paper and gloves), acid waste, and expired chemicals that are stored at the facility. 

This facility makes the university a safer place because there are less toxic and flammable waste lying around in the labs. – Tinus Viljoen

Adhering to legislation

He explains that he is notified by departments in the Faculty of Natural and Agricultural Sciences when they have waste to collect and that he then collects it on Fridays.

Viljoen continues: “The chemical waste is then classified according to the various waste streams and stored in large 210 l drums. When the drums are full, I contact an accredited hazardous waste company to remove, transport, and dispose of the various waste according to strict legislation, constituting the National Environmental Management Act (Act 107 of 1998), the National Environmental Management: Waste Act, 2008 (Act 59 of 2008), the Hazardous Substances Act (Act 5 of 1973), and the National Road Traffic Act, 93 of 1996 (NRTA).”

“The majority of the waste is transported to a hazardous landfill in Gauteng and the rest are incinerated,” he concludes. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept